Physician profile
Bruce Lee Wolf
NPI 1932191855
$14,556.76
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $840 · 2020: $7,485 · 2021: $6,103 · 2022: $129.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $13,481.94 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $310.62 | 2019-2021 | |
| Csl Behring | $219.99 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $110.48 | 2019-2022 | |
| Genzyme Corporation | $109.29 | 2019 | |
| Lemaitre Vascular, INC. | $67.10 | 2019 | |
| Alk-Abello, INC | $43.39 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $43.12 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $36.59 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.07 | 2021 | |
| Amgen INC. | $22.92 | 2022 | |
| Shire North American Group INC | $22.23 | 2019 | |
| Genentech USA, INC. | $15.78 | 2019 | |
| Kaleo, INC. | $15.05 | 2019 | |
| Pfizer INC. | $12.44 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $11.69 | 2019 | |
| Sunovion Pharmaceuticals INC. | $10.06 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.